ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$225.10
−2.43%Price chart
Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21
Key dataOct 21, 2026
Open$227.86
From 52W high−53.26%
Volume1.18M
Market cap$30.12B
P/E (TTM)36.9x
P/S (TTM)6.3x
Div yield—
Key dataOct 21, 2026
Open
$227.86
From 52W high
−53.26%
Volume
1.18M
Market cap
$30.12B
ValuationView details →
P/E (Fwd)
24.7x
EV/EBITDA
24.4x
P/E (TTM)
36.9x
RSI (14)
42.8
MomentumView details →
1D Return
−2.43%
YTD Return
−43.11%
SummaryUpdated Jun 1, 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a pioneering biopharmaceutical company founded in 2002 and headquartered in Cambridge, Massachusetts. The company went public in 2004 and has established itself as a leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating diseases by silencing specific genes that cause illness. Alnylam has successfully commercialized multiple RNAi-based medicines and maintains a robust pipeline targeting both rare genetic diseases and more prevalent conditions including cardiovascular, metabolic, and neurological disorders.
Similar companies
Latest newsMore news →
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.55d agoAlnylam Pharmaceuticals announced it will present new clinical and real-world data across its ATTR and hypertension programs at the ESC Congress 2026 in Munich, Germany, from August 28-31, 2026.59d ago